Loading...
•
Mar 28, 2020
Haemonetics Q4 2020 Earnings Report
Haemonetics' Q4 2020 results were reported, revealing a decrease in revenue but an increase in gross margin and operating income compared to the same period last year.
Key Takeaways
Haemonetics reported a decrease in revenue for Q4 2020, with a 4.3% drop to $238.5 million. However, the company saw improvements in gross margin, which rose by 300 basis points to 47.6%, and operating income, which increased by 9.0% to $26.0 million. Net income decreased by 15.4% to $17.6 million, with earnings per diluted share down 15.0% to $0.34.
Q4 2020 revenue decreased by 4.3% to $238.5 million.
Gross margin increased by 300 basis points to 47.6%.
Operating income increased by 9.0% to $26.0 million.
Net income decreased by 15.4% to $17.6 million.
Revenue by Segment
Forward Guidance
Given the uncertainty around the full impact and duration of the COVID-19 pandemic, and the nature and timing of the associated economic recovery, Haemonetics is not issuing annual guidance at this time. The Company is currently assessing potential scenarios for the macroeconomic impact of COVID-19 and the related effect on healthcare beyond the current quarter, informed by milestones and market indicators that unfold over the coming weeks. As a result the Company intends to issue guidance later in its fiscal year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...